A prospectively maintained Dutch registry reveals over 70% of patients acheiving a complete clinical response to upfront immune checkpoint inhibition for stage III-IV melanoma remain without evidence of disease 3 years out from response after which curves continue at a plateau. | van Not, JAMA Netw Open 2024

